Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Positron lymphography via intracervical 18F-FDG injection for pre-surgical lymphatic mapping in cervical and endometrial malignancies.

Mueller JJ, Dauer LT, Murali R, Iasonos A, Pandit-Taskar N, Abu-Rustum N, Grimm J.

J Nucl Med. 2020 Jan 10. pii: jnumed.119.230714. doi: 10.2967/jnumed.119.230714. [Epub ahead of print]

PMID:
31924717
2.

First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting.

Pandit-Taskar N, Postow M, Hellmann M, Harding J, Barker C, O'Donoghue J, Ziolkowska M, Ruan S, Lyashchenko S, Tsai F, Farwell M, Mitchell T, Korn R, Le W, Lewis J, Weber W, Behera D, Wilson I, Gordon M, Wu A, Wolchok J.

J Nucl Med. 2019 Oct 4. pii: jnumed.119.229781. doi: 10.2967/jnumed.119.229781. [Epub ahead of print]

PMID:
31586002
3.

Restaging FDG-PET/CT scan in recurrent cutaneous SCC: Diagnostic performance and prognostic significance.

Mahajan S, Barker CA, Mauguen A, Singh B, Pandit-Taskar N.

J Am Acad Dermatol. 2019 Sep 25. pii: S0190-9622(19)32780-X. doi: 10.1016/j.jaad.2019.09.035. [Epub ahead of print]

PMID:
31562942
4.

Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer.

Lohrmann C, O'Reilly EM, O'Donoghue JA, Pandit-Taskar N, Carrasquillo JA, Lyashchenko SK, Ruan S, Teng R, Scholz W, Maffuid PW, Lewis JS, Weber WA.

Clin Cancer Res. 2019 Dec 1;25(23):7014-7023. doi: 10.1158/1078-0432.CCR-18-3667. Epub 2019 Sep 20.

PMID:
31540979
5.

Targeted Radioimmunotherapy and Theranostics with Alpha Emitters.

Pandit-Taskar N.

J Med Imaging Radiat Sci. 2019 Dec;50(4S1):S41-S44. doi: 10.1016/j.jmir.2019.07.006. Epub 2019 Aug 23.

PMID:
31451417
6.

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.

Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gönen M, Lohrmann C, Bodei L, Weber WA.

Clin Cancer Res. 2019 Dec 1;25(23):6939-6947. doi: 10.1158/1078-0432.CCR-19-1026. Epub 2019 Aug 22.

PMID:
31439583
7.

Biodistribution and Dosimetry of Intraventricularly Administered 124I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.

Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, Zhang Z, Lyashchenko SK, Fung AM, Pentlow KS, Carrasquillo JA, Lewis JS, Larson SM, Cheung NV, Humm JL.

J Nucl Med. 2019 Dec;60(12):1794-1801. doi: 10.2967/jnumed.118.219576. Epub 2019 Aug 12.

PMID:
31405921
8.

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D, Virgolini IJ, Fanti S, Balogova S, Pandit-Taskar N, Pacak K.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137. doi: 10.1007/s00259-019-04398-1. Epub 2019 Jun 29.

PMID:
31254038
9.

89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo.

Jauw YWS, O'Donoghue JA, Zijlstra JM, Hoekstra OS, Menke-van der Houven van Oordt CW, Morschhauser F, Carrasquillo JA, Zweegman S, Pandit-Taskar N, Lammertsma AA, van Dongen GAMS, Boellaard R, Weber WA, Huisman MC.

J Nucl Med. 2019 Dec;60(12):1825-1832. doi: 10.2967/jnumed.118.224568. Epub 2019 May 30.

PMID:
31147401
10.

Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.

O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G, Lyashchenko SK, Williams SP, Scher HI, Fine BM, Humm JL, Larson SM, Morris MJ, Carrasquillo JA.

Mol Pharm. 2019 Jul 1;16(7):3083-3090. doi: 10.1021/acs.molpharmaceut.9b00326. Epub 2019 May 31.

PMID:
31117485
11.

Clinical value of 18F-FDG-PET/CT in staging cutaneous squamous cell carcinoma.

Mahajan S, Barker CA, Singh B, Pandit-Taskar N.

Nucl Med Commun. 2019 Jul;40(7):744-751. doi: 10.1097/MNM.0000000000001029.

PMID:
31095044
12.

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.

Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS.

Eur J Cancer. 2019 Jun;114:107-116. doi: 10.1016/j.ejca.2019.04.007. Epub 2019 May 11.

13.

Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.

Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, Cheal SM, O'Donoghue JA, Ruan S, Ragupathi G, Lyashchenko SK, Humm JL, Scher HI, Gönen M, Williams SP, Danila DC, Morris MJ.

J Nucl Med. 2019 Nov;60(11):1517-1523. doi: 10.2967/jnumed.118.222844. Epub 2019 May 3.

PMID:
31053681
14.

Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.

Bailey K, Pandit-Taskar N, Humm JL, Zanzonico P, Gilheeney S, Cheung NV, Kramer K.

J Neurooncol. 2019 May;143(1):101-106. doi: 10.1007/s11060-019-03139-6. Epub 2019 Mar 16.

PMID:
30879172
15.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
16.

Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.

Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, O'Donoghue JA.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):677-685. doi: 10.1007/s00259-018-4193-y. Epub 2018 Oct 29.

PMID:
30374529
17.

Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.

Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NV, Larson SM, Dunkel IJ.

Lancet Oncol. 2018 Aug;19(8):1040-1050. doi: 10.1016/S1470-2045(18)30322-X. Epub 2018 Jun 18. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382.

18.

Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods.

Pandit-Taskar N.

Semin Hematol. 2018 Jan;55(1):22-32. doi: 10.1053/j.seminhematol.2018.02.009. Epub 2018 Mar 5. Review.

PMID:
29759149
19.

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma.

Carrasquillo JA, O'Donoghue JA, Beylergil V, Ruan S, Pandit-Taskar N, Larson SM, Smith-Jones PM, Lyashchenko SK, Ohishi N, Ohtomo T, Abou-Alfa GK.

EJNMMI Res. 2018 Mar 5;8(1):20. doi: 10.1186/s13550-018-0374-8.

20.

Patient-specific organ and effective dose estimates in pediatric oncology computed tomography.

Gao Y, Quinn B, Pandit-Taskar N, Behr G, Mahmood U, Long D, Xu XG, St Germain J, Dauer LT.

Phys Med. 2018 Jan;45:146-155. doi: 10.1016/j.ejmp.2017.12.013. Epub 2017 Dec 22.

21.

Solitary Orbital Metastasis in Carcinoma Esophagus: Findings on Serial 18F-FDG PET/CT Scans.

Mahajan S, Dunphy MP, Haque S, Pandit-Taskar N.

Clin Nucl Med. 2018 Jan;43(1):19-22. doi: 10.1097/RLU.0000000000001892.

PMID:
29135612
22.

Uncommon Metastasis to the Pancreas From Adenocarcinoma of the Cervix Detected on Surveillance 18F-FDG PET/CT Imaging.

Mahajan S, Pandit-Taskar N.

Clin Nucl Med. 2017 Dec;42(12):e511-e512. doi: 10.1097/RLU.0000000000001849.

PMID:
29035993
23.

A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma.

Kramer K, Pandit-Taskar N, Humm JL, Zanzonico PB, Haque S, Dunkel IJ, Wolden SL, Donzelli M, Goldman DA, Lewis JS, Lyashchenko SK, Khakoo Y, Carrasquillo JA, Souweidane MM, Greenfield JP, Lyden D, De Braganca KD, Gilheeney SW, Larson SM, Cheung NV.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26754. Epub 2017 Sep 22.

24.

Norepinephrine Transporter as a Target for Imaging and Therapy.

Pandit-Taskar N, Modak S.

J Nucl Med. 2017 Sep;58(Suppl 2):39S-53S. doi: 10.2967/jnumed.116.186833. Review.

25.

Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer.

Cornelis FH, Durack JC, Pandit-Taskar N, Ulaner GA, Lewis JS, Morris MJ, Solomon SB.

J Nucl Med. 2018 Mar;59(3):399-402. doi: 10.2967/jnumed.117.194480. Epub 2017 Aug 17.

26.

Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.

Pandit-Taskar N, Zanzonico P, Hilden P, Ostrovnaya I, Carrasquillo JA, Modak S.

Clin Nucl Med. 2017 Oct;42(10):741-748. doi: 10.1097/RLU.0000000000001752.

27.

Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, Burnazi E, Zhang H, Lewis JS, Blasberg R, Larson SM, Weber WA, Modak S.

J Nucl Med. 2018 Jan;59(1):147-153. doi: 10.2967/jnumed.117.193169. Epub 2017 Jul 13.

28.

Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer.

O'Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schöder H, Larson SM, Beylergil V, Ruan S, Lyashchenko SK, Zanzonico PB, Weber WA, Carrasquillo JA, Janjigian YY.

J Nucl Med. 2018 Jan;59(1):161-166. doi: 10.2967/jnumed.117.194555. Epub 2017 Jun 21.

29.

The Precision of Hepatic Arterial Infusion Scintigraphy as a Quantitative Biomarker of Tumor Microvasculature.

Dunphy M, Pandit-Taskar N, Fox JJ, Kemeny N.

AJR Am J Roentgenol. 2017 Jul;209(1):182-186. doi: 10.2214/AJR.16.17560. Epub 2017 May 24.

30.

A comparison of pediatric and adult CT organ dose estimation methods.

Gao Y, Quinn B, Mahmood U, Long D, Erdi Y, St Germain J, Pandit-Taskar N, Xu XG, Bolch WE, Dauer LT.

BMC Med Imaging. 2017 Apr 26;17(1):28. doi: 10.1186/s12880-017-0199-3.

31.

Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma.

Sait S, Pandit-Taskar N, Modak S.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26549. Epub 2017 Apr 14.

PMID:
28409892
32.

Multifocal Osteosarcoma: Unusual Presentation and Imaging Findings.

Gavane S, Price AP, Magnan H, Mahajan S, Pandit-Taskar N.

Clin Nucl Med. 2017 Apr;42(4):e202-e206. doi: 10.1097/RLU.0000000000001560.

PMID:
28166155
33.

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).

Abou-Alfa GK, Yen CJ, Hsu CH, O'Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko SK, Ma J, Wan P, Shao YY, Lin ZZ, Frenette C, O'Neil B, Schwartz L, Smith-Jones PM, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen YC, Agajanov T, Boisserie F, Di Laurenzio L, Lee R, Larson SM, Cheng AL, Carrasquilo JA.

Cancer Chemother Pharmacol. 2017 Feb;79(2):421-429. doi: 10.1007/s00280-017-3241-9. Epub 2017 Jan 24.

34.

Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.

Sait S, Kobos R, LaQuaglia MP, Pandit-Taskar N, Modak S.

Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26314. Epub 2016 Nov 2.

35.

Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.

Pandit-Taskar N, Veach DR, Fox JJ, Scher HI, Morris MJ, Larson SM.

J Nucl Med. 2016 Oct;57(Suppl 3):73S-78S.

36.

First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.

Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, Larson SM, Morris MJ.

J Nucl Med. 2016 Dec;57(12):1858-1864. Epub 2016 Aug 11.

37.

Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.

Shady W, Sotirchos VS, Do RK, Pandit-Taskar N, Carrasquillo JA, Gonen M, Sofocleous CT.

AJR Am J Roentgenol. 2016 Sep;207(3):661-70. doi: 10.2214/AJR.15.15202. Epub 2016 Jul 6.

38.

Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates.

Quinn B, Dauer Z, Pandit-Taskar N, Schoder H, Dauer LT.

BMC Med Imaging. 2016 Jun 18;16(1):41. doi: 10.1186/s12880-016-0143-y.

39.

I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.

Carrasquillo JA, Pandit-Taskar N, Chen CC.

Semin Nucl Med. 2016 May;46(3):203-14. doi: 10.1053/j.semnuclmed.2016.01.011. Review.

PMID:
27067501
40.

Molecular Imaging of Biomarkers in Breast Cancer.

Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W.

J Nucl Med. 2016 Feb;57 Suppl 1:53S-9S. doi: 10.2967/jnumed.115.157909. Review.

41.

Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.

Chu BP, Horan C, Basu E, Dauer L, Williamson M, Carrasquillo JA, Pandit-Taskar N, Modak S.

Pediatr Blood Cancer. 2016 May;63(5):801-7. doi: 10.1002/pbc.25892. Epub 2016 Jan 15.

42.

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.

Modak S, Zanzonico P, Carrasquillo JA, Kushner BH, Kramer K, Cheung NK, Larson SM, Pandit-Taskar N.

J Nucl Med. 2016 Feb;57(2):231-7. doi: 10.2967/jnumed.115.161752. Epub 2016 Jan 7.

43.

Foot and Ankle Hepatocellular Carcinoma Metastasis.

Parashar K, Pandit-Taskar N.

Clin Nucl Med. 2016 Jan;41(1):69-71. doi: 10.1097/RLU.0000000000001009.

PMID:
26447372
44.

Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes.

Sofocleous CT, Violari EG, Sotirchos VS, Shady W, Gonen M, Pandit-Taskar N, Petre EN, Brody LA, Alago W, Do RK, D'Angelica MI, Osborne JR, Segal NH, Carrasquillo JA, Kemeny NE.

Clin Colorectal Cancer. 2015 Dec;14(4):296-305. doi: 10.1016/j.clcc.2015.06.003. Epub 2015 Jun 27.

45.

PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.

Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Smith-Jones P, Ruan S, Divgi C, Scott AM, Kemeny NE, Fong Y, Wong D, Scheinberg D, Ritter G, Jungbluth A, Old LJ, Larson SM.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1700-1706. doi: 10.1007/s00259-015-3061-2. Epub 2015 Jul 21.

46.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD.

Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14.

47.

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gönen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ.

Clin Cancer Res. 2015 Dec 1;21(23):5277-85. doi: 10.1158/1078-0432.CCR-15-0552. Epub 2015 Jul 14.

48.

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ.

EJNMMI Res. 2015 Apr 29;5:28. doi: 10.1186/s13550-015-0104-4. eCollection 2015.

49.

Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy.

Kramer K, Pandit-Taskar N, Zanzonico P, Wolden SL, Humm JL, DeSelm C, Souweidane MM, Lewis JS, Cheung NK.

J Neurooncol. 2015 Jun;123(2):245-9. doi: 10.1007/s11060-015-1788-z. Epub 2015 May 6.

50.

PET Imaging of Breast Cancer: Role in Patient Management.

Lebron L, Greenspan D, Pandit-Taskar N.

PET Clin. 2015 Apr;10(2):159-95. doi: 10.1016/j.cpet.2014.12.004. Review.

PMID:
25829085

Supplemental Content

Loading ...
Support Center